Radius Health, a US-based developer of drug therapies for osteoporosis and women’s health backed by Switzerland-based peer Novartis, has raised $43m after pulling its planned stock market flotation at the end of last year. Novartis’s pharmaceutical business unit invested in Radius’ latest round through its joint programme with venture capital firm MPM Capital’s MPM Bio IV NVS Strategic Fund. The other investors were MPM’s main venture fund and VC peers F2 Biosciences III, Biotech Growth, Brookside Capital and BB Biotech Ventures. Morana Jovan-Embiricos, managing partner at F2 Biosciences, and Owen Hughes, chief business officer and head of corporate development at Intarcia Therapeutics and formerly a director at Brookside Capital, will join Radius’ board. In December, Radius postponed its initial public offering (IPO), citing market conditions. The company had planned to sell 6.5 million shares at between $8.50 and $10.50 per share, and trade on the Nasdaq, as stated in a filing in February. Investment banks UBS and Leerink Swann were to serve as co-lead underwriters. Radius Health had previously raised more than $170m in funding from firms including MPM Capital, The Wellcome Trust (13.4%), HealthCare Ventures (10.7%), BB Biotech Ventures (8.9%), Saints Capital (8.7%), Oxford Bioscience Partners (6.4%), Brookside Capital (5.7%), Nordic Bioscience, Ipsen Pharma and the Scottish Widows Investment Partnership.
- News & Analysis
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Deal Data
- Community & Events
Radius glows with $43m
Apr 26, 2013 • Global Corporate Venturing
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
Featured ContentFUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database.
FUNDING ROUND DATA
Which corporates are backing which startups? Search our corporate deal database.NOMINATE Nominations for the GCV Powerlist 2024 are now open
Nominations for the GCV Powerlist 2024 are now openEventsWebinar: Startups and Strategics – What works and what doesn’tEventsGCV Institute: Landing the Value of Corporate VenturingTop News
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.test reg